An evaluation of palbociclib as a breast cancer treatment option: a current update.

Expert Opinion on Pharmacotherapy
Gregory T GallanisPaula R Pohlmann

Abstract

Patients with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer have benefitted from treatment with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor capable of selectively targeting mechanisms of cell cycle progression that contribute to tumor cell proliferation. Palbociclib use in this setting demonstrates improved progression-free survival when given in combination with aromatase inhibitors or fulvestrant. The authors describe the current state of research surrounding palbociclib use in breast cancer, present evidence supporting a role for palbociclib in additional subtypes of metastatic breast cancer such as HER2-positive (HER2+) and triple-negative, report ongoing clinical trials aimed at expanding the scope of use for palbociclib, and discuss expected clinical results that will better inform decisions on including palbociclib as a part of breast cancer treatment strategies. Preclinical and clinical studies have shown promising evidence for palbociclib use in metastatic HER2+ and androgen receptor-expressing triple-negative breast cancer but mixed results in the adjuvant/neoadjuvant setting, where differences may only be detectable in high-risk disease. Palbociclib combinations may const...Continue Reading

References

Dec 1, 1993·Genes & Development·D CobrinikR A Weinberg
May 1, 1993·Genes & Development·V BaldinG Draetta
Feb 7, 1997·Cell·R M ZwijsenR J Michalides
Sep 1, 1997·Molecular and Cellular Biology·E NeumanM E Ewen
May 3, 2002·The Journal of Biological Chemistry·Meng-Min LiuPeter J Kushner
Feb 8, 2003·Current Opinion in Genetics & Development·Scott W Lowe, Charles J Sherr
Nov 19, 2004·Nature·Joan Massagué
Jan 18, 2006·Cancer Cell·Qunyan YuPiotr Sicinski
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Mar 28, 2008·Nature Cell Biology·Guang YaoLingchong You
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Nov 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keith T FlahertyGary K Schwartz
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 20, 2012·Cancer Cell·Yoon Jong ChoiPiotr Sicinski
Aug 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ayca GucalpUNKNOWN Translational Breast Cancer Research Consortium (TBCRC 011)
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angela DeMichelePeter O'Dwyer
Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Dec 15, 2015·Cancer Discovery·Charles J SherrGeoffrey I Shapiro
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Mar 9, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cynthia X MaMatthew J Ellis
Jun 14, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Uzma S AsgharNicholas C Turner
Aug 17, 2017·Nature·Shom GoelJean J Zhao
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Sep 19, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Malaka AmeratungaJuanita S Lopez

❮ Previous
Next ❯

Citations

Jul 17, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Runtian WangXiaoxiang Guan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.